• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Antipsychotics in Pregnancy and Risk of Neurodevelopmental Disorders
Research Update

Antipsychotics in Pregnancy and Risk of Neurodevelopmental Disorders

October 3, 2023
Sébastien Hardy, PharmD, BCPS.
From The Carlat Hospital Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Sébastien Hardy, PharmD, BCPS. Dr. Hardy has no financial relationships with companies related to this material.

REVIEW OF: Straub L et al, JAMA Intern Med 2022;182(5):522–533

STUDY TYPE: Retrospective cohort study

We sometimes prescribe antipsychotic medications to pregnant women with psychiatric disorders, but might these medications affect children’s developmental outcomes? Antipsychotic drugs readily cross the placenta, but available data about the risk of congenital malformations in exposed children are generally reassuring (Huybrechts KF et al, JAMA Psychiatry 2016;73(9):938–946). However, we know little about neurodevelopmental outcomes following prenatal antipsychotic exposures, particularly for ­second-generation antipsychotics. 

A recent US-based retrospective cohort study examined the risk of neurodevelopmental disorders (eg, ADHD, autism spectrum disorder, learning disability, or intellectual disability) in children following gestational exposure to antipsychotics. The study reviewed databases of publicly and privately insured women from 2000 to 2015. Children were considered exposed if their mothers filled antipsychotic prescriptions after 18 weeks of gestation. Why was the second half of pregnancy chosen? Synaptogenesis—the formation of nerve synapses—begins at this fetal stage. 

Exposed (n=10,772) and unexposed (n=3,341,291) children were matched on potential confounders, including age, treatment indications, severity of underlying mental illnesses, adjunctive medications, maternal comorbidities, and socioeconomic status. Exposures were to first-generation and second-generation antipsychotics, with quetiapine being the most dispensed, followed by aripiprazole, risperidone, olanzapine, and haloperidol. Most women took only one antipsychotic during pregnancy, and children were followed up to 14 years. 

In the initial, unadjusted analyses, gestational exposure to antipsychotics was linked to an almost twofold increase in the risk of neurodevelopmental disorders, with a hazard ratio (HR) of 1.9. However, after accounting for confounding variables, this increase was no longer statistically significant, showing an adjusted HR of 1.1. The exception was aripiprazole, which still demonstrated a small yet statistically significant elevated risk for neurodevelopmental disorders.

The extensive scale of this epidemiological study, sourced from nationwide health care utilization databases and featuring long-term follow-up periods, offers valuable insights into the statistical associations related to rare occurrences, such as neurodevelopmental disorders.

Carlat Take

Treatment decisions in pregnancy require careful balancing of risks and benefits. This large cohort study provides reassuring data about neurodevelopmental outcomes in children exposed to second-generation antipsychotic medications during the second half of pregnancy. The increased risk identified with prenatal aripiprazole requires further study before we can conclude whether it should change our prescribing practices.

Hospital Psychiatry Research Update
KEYWORDS antipsychotics aripiprazole children infant neurodevelopment pregnancy second generation antipsychotic
    Sébastien Hardy, PharmD, BCPS.

    Sublingual Dexmedetomidine for Acute Agitation in Bipolar Disorder

    More from this author
    www.thecarlatreport.com
    Issue Date: October 3, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Reproductive Psychiatry, CHPR, October/November/December 2023
    Postpartum Psychosis: A Primer
    Treating Bipolar Disorder During Pregnancy
    Management of Depression During Pregnancy and Breastfeeding
    Diagnosing and Treating Postpartum Depression
    Antipsychotics in Pregnancy and Risk of Neurodevelopmental Disorders
    Long-Acting Injectable Antipsychotics and Risk of Hospitalization
    CME Post-Test, Reproductive Psychiatry, CHPR, October/November/December 2023
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.